These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 29194765)

  • 21. C-kit as a prognostic and therapeutic marker in canine cutaneous mast cell tumours: From laboratory to clinic.
    Gil da Costa RM
    Vet J; 2015 Jul; 205(1):5-10. PubMed ID: 26021891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proof of target for SU11654: inhibition of KIT phosphorylation in canine mast cell tumors.
    Pryer NK; Lee LB; Zadovaskaya R; Yu X; Sukbuntherng J; Cherrington JM; London CA
    Clin Cancer Res; 2003 Nov; 9(15):5729-34. PubMed ID: 14654558
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Concordance of c-kit mutational status in matched primary and metastatic cutaneous canine mast cell tumors at baseline.
    Marconato L; Zorzan E; Giantin M; Di Palma S; Cancedda S; Dacasto M
    J Vet Intern Med; 2014; 28(2):547-53. PubMed ID: 24372836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic alterations of KIT during clonal expansion and subsequent acquisition of resistance to toceranib in a canine mast cell tumor cell line.
    Kurita S; Miyamoto R; Tani H; Kobayashi M; Sasaki T; Tamura K; Bonkobara M
    J Vet Pharmacol Ther; 2019 Nov; 42(6):673-681. PubMed ID: 31553064
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision.
    London CA; Malpas PB; Wood-Follis SL; Boucher JF; Rusk AW; Rosenberg MP; Henry CJ; Mitchener KL; Klein MK; Hintermeister JG; Bergman PJ; Couto GC; Mauldin GN; Michels GM
    Clin Cancer Res; 2009 Jun; 15(11):3856-65. PubMed ID: 19470739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. All subunits of the interleukin-2 receptor are expressed by canine cutaneous mast cell tumours.
    Meyer A; Gruber AD; Klopfleisch R
    J Comp Pathol; 2013 Jul; 149(1):19-29. PubMed ID: 23276382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cellular proliferation in canine cutaneous mast cell tumors: associations with c-KIT and its role in prognostication.
    Webster JD; Yuzbasiyan-Gurkan V; Miller RA; Kaneene JB; Kiupel M
    Vet Pathol; 2007 May; 44(3):298-308. PubMed ID: 17491070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I dose escalation of single-agent vinblastine in dogs.
    Bailey DB; Rassnick KM; Kristal O; Chretin JD; Balkman CE
    J Vet Intern Med; 2008; 22(6):1397-402. PubMed ID: 19000250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Successful treatment of a metastatic, gastrointestinal stromal tumour in a dog with toceranib phosphate (Palladia).
    Elliott JW; Swinbourne F; Parry A; Baines L
    J Small Anim Pract; 2017 Jul; 58(7):416-418. PubMed ID: 28199021
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
    Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
    Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs.
    Yamazaki H; Miura N; Lai YC; Takahashi M; Goto-Koshino Y; Yasuyuki M; Nakaichi M; Tsujimoto H; Setoguchi A; Endo Y
    J Vet Med Sci; 2017 Jul; 79(7):1225-1229. PubMed ID: 28592719
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma cytokeratin-18 concentrations as noninvasive biomarker of early gastrointestinal toxicosis in dogs receiving toceranib.
    Kovac RL; Ballash G; Fenger J; London C; Warry E
    J Vet Intern Med; 2018 Nov; 32(6):2061-2068. PubMed ID: 30353992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety evaluation of combination vinblastine and toceranib phosphate (Palladia®) in dogs: a phase I dose-finding study.
    Robat C; London C; Bunting L; McCartan L; Stingle N; Selting K; Kurzman I; Vail DM
    Vet Comp Oncol; 2012 Sep; 10(3):174-83. PubMed ID: 22235914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib elicited a favorable response in a dog with a mast cell tumor carrying a c-kit c.1523A>T mutation via suppression of constitutive KIT activation.
    Yamada O; Kobayashi M; Sugisaki O; Ishii N; Ito K; Kuroki S; Sasaki Y; Isotani M; Ono K; Washizu T; Bonkobara M
    Vet Immunol Immunopathol; 2011 Jul; 142(1-2):101-6. PubMed ID: 21561667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of postoperative adjuvant treatment using toceranib phosphate against adenocarcinoma in dogs.
    Yamazaki H; Tanaka T; Mie K; Nishida H; Miura N; Akiyoshi H
    J Vet Intern Med; 2020 May; 34(3):1272-1281. PubMed ID: 32267594
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
    Berger EP; Johannes CM; Jergens AE; Allenspach K; Powers BE; Du Y; Mochel JP; Fox LE; Musser ML
    J Vet Intern Med; 2018 Nov; 32(6):2045-2053. PubMed ID: 30307656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Survival and Glycemic Control with Toceranib Phosphate and Prednisone for a Metastatic Canine Insulinoma.
    Flesner BK; Fletcher JM; Smithee T; Boudreaux B
    J Am Anim Hosp Assoc; 2019; 55(1):e55105. PubMed ID: 30427714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prospective evaluation of toceranib phosphate in metastatic canine osteosarcoma.
    Laver T; London CA; Vail DM; Biller BJ; Coy J; Thamm DH
    Vet Comp Oncol; 2018 Mar; 16(1):E23-E29. PubMed ID: 28621057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retrospective evaluation of toceranib (Palladia) treatment for canine metastatic appendicular osteosarcoma.
    Kim C; Matsuyama A; Mutsaers AJ; Woods JP
    Can Vet J; 2017 Oct; 58(10):1059-1064. PubMed ID: 28966355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Maintenance therapy with toceranib following doxorubicin-based chemotherapy for canine splenic hemangiosarcoma.
    Gardner HL; London CA; Portela RA; Nguyen S; Rosenberg MP; Klein MK; Clifford C; Thamm DH; Vail DM; Bergman P; Crawford-Jakubiak M; Henry C; Locke J; Garrett LD
    BMC Vet Res; 2015 Jun; 11():131. PubMed ID: 26062540
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.